Sunny Lee Ryan
Keine laufenden Positionen mehr
Profil
Sunny Lee Ryan worked as an Auditor at Pricewaterhousecoopers LLC from 1993 to 2001.
From 2001 to 2005, she worked as a Senior Director-Finance & Controller at Genelabs Technologies, Inc. She then worked as a Controller at Rinat Neuroscience Corp.
from 2005 to 2006.
From 2006 to 2008, she worked as a Senior Director-Finance & Controller at CoMentis, Inc. From 2008 to 2011, she worked as a Director-Finance & Controller at Achaogen, Inc. She then worked as a Controller at Alios BioPharma, Inc. from 2011 to 2012.
From 2013 to 2014, she worked as an Interim Controller at Adverum Biotechnologies, Inc. From 2016 to 2020, she worked as a Vice President-Finance at Menlo Therapeutics, Inc. From 2020 to 2021, she worked as an Executive Vice President-Finance at Biomea Fusion, Inc. Ms. Ryan received her undergraduate degree from Pepperdine University.
Ehemalige bekannte Positionen von Sunny Lee Ryan
| Unternehmen | Position | Ende |
|---|---|---|
| BIOMEA FUSION, INC. | Finanzdirektor/CFO | 26.07.2021 |
| VYNE THERAPEUTICS INC. | Corporate Officer/Principal | 01.05.2020 |
| ADVERUM BIOTECHNOLOGIES, INC. | Comptroller/Controller/Auditor | 01.01.2014 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01.01.2012 |
| ACHAOGEN | Comptroller/Controller/Auditor | 01.01.2011 |
Ausbildung von Sunny Lee Ryan
| Pepperdine University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOMEA FUSION, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Rinat Neuroscience Corp.
 Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | Health Technology |
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Health Technology |
| Pricewaterhousecoopers LLC |
